Table 2.
Prescription characteristics of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors
| Medication | Mean Continuous Use, d (SD) | Median Continuous Use, d (Interquartile Range) |
|---|---|---|
| SGLT2i | ||
| All, n=38,994 | 428 (414) | 287 (89–645) |
| Empagliflozin, n=22,095 | 379 (342) | 283 (85–566) |
| Canagliflozin, n=11,939 | 464 (477) | 272 (78–711) |
| Dapagliflozin, n=4960 | 414 (368) | 291 (91–664) |
| DPP-4i | ||
| All, n=105,700 | 501 (454) | 348 (135–778) |
| Sitagliptin, n=78,633 | 480 (443) | 329 (125–733) |
| Linagliptin, n=22,415 | 504 (452) | 358 (125–794) |
| Saxagliptin, n=4652 | 470 (462) | 283 (104–723) |
SGLT2i, sodium-glucose cotransporter-2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor.